CA3288582A1 - Utilisation médicale d'anticorps bispécifique anti-ctla4 et anti-pd-1 - Google Patents

Utilisation médicale d'anticorps bispécifique anti-ctla4 et anti-pd-1

Info

Publication number
CA3288582A1
CA3288582A1 CA3288582A CA3288582A CA3288582A1 CA 3288582 A1 CA3288582 A1 CA 3288582A1 CA 3288582 A CA3288582 A CA 3288582A CA 3288582 A CA3288582 A CA 3288582A CA 3288582 A1 CA3288582 A1 CA 3288582A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
set forth
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3288582A
Other languages
English (en)
Inventor
Baiyong Li
Yu Xia
Zhongmin Wang
Original Assignee
Akeso Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Pharma Co Ltd filed Critical Akeso Pharma Co Ltd
Publication of CA3288582A1 publication Critical patent/CA3288582A1/fr
Pending legal-status Critical Current

Links

CA3288582A 2023-04-10 2024-04-10 Utilisation médicale d'anticorps bispécifique anti-ctla4 et anti-pd-1 Pending CA3288582A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310378536.6 2023-04-10

Publications (1)

Publication Number Publication Date
CA3288582A1 true CA3288582A1 (fr) 2026-01-19

Family

ID=

Similar Documents

Publication Publication Date Title
JP7655896B2 (ja) 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
EP4067387A1 (fr) Anticorps bispécifique anti-pd-1-anti-vegfa, composition pharmaceutique et leur utilisation
WO2018036472A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
WO2018036473A1 (fr) Anticorps bifonctionnel anti-ctla4 et anti-pd -1, composition pharmaceutique et utilisation associées
WO2017071625A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
EP4483877A1 (fr) Composition pharmaceutique comprenant un anticorps bispécifique anti-ctla4-anti-pd-1 et du chiauranib
JP2024528682A (ja) 薬物組成物及び用途
WO2024051223A1 (fr) Composition pharmaceutique et son utilisation
EP4357367A1 (fr) Composition pharmaceutique et son utilisation
EP4696715A1 (fr) Utilisation médicale d'anticorps bispécifique anti-ctla4 et anti-pd-1
EP4678186A1 (fr) Composition pharmaceutique comprenant un anticorps bispécifique anti-ctla4-anti-pd-1 et son utilisation
JP2026515464A (ja) 抗ｃｔｌａ４抗ｐｄ－１二重特異性抗体の医薬用途
HK40114887A (zh) 抗ctla4-抗pd-1双特异性抗体的医药用途
CA3285164A1 (fr) Composition pharmaceutique comprenant un anticorps bispécifique anti-ctla4-anti-pd-1 et son utilisation
HK40117394A (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib
AU2024341649A1 (en) Pharmaceutical combination and use
HK40109390A (zh) 药物组合及用途
HK40080672A (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
EA049587B1 (ru) Биспецифическое антитело против ctla4/против pd-1 и его применение